Figure 4.
In silico docking studies representing 2 dimentional Azima tetracantha complexes with ligand interaction. (A) Compound 1, [5,6-dimethoxy-3-methyl-2,3-dihydro-1H-indene-1-oneintertaction 4AGD]. (B) Compound 2, [5-(4- aminophenyl)-4-(o-tolyl) thiazol-2-amine]. (C) Compound 3, [2-(3-acetoxy-4,4,10,13,14-pentamethyl- 2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl) propanoic acid]. (D) Compound 4, [7-acetyl-3a1-methyl-4,14-dioxo1,2,3a,3a1,4,5,5a,6,8a,9b,10,11,11a-tetradecahydro-2,5a1-epoxy5,6a(methanooxymethano)phenaleno[1′,9′:5,6,7]indeno[1,7a-b]oxiren-2-yl acetate].